UK Updates

UK’s 2025 Roadmap to Phase Out Animal Testing

UK Government Announces New Medical Device Regulations

On December 15, 2025, the UK government announced a plan to gradually introduce new regulations for medical devices. This aims to improve patient safety, encourage innovation, and prevent supply issues, ensuring that the UK remains a top choice for med-tech companies.

Key Areas of the Reform

1. Patient Safety

  • Improve post market surveillance (PMS) requirements to detect safety signals, monitor device performance, and ensure timely corrective actions.
  • Stronger vigilance systems to protect patients and keep public trust

2. Encouraging Innovation

  • Balanced rules for software and AI enabled devices, recognizing the fast growth in digital health.
  • Faster approval for breakthrough technologies, while ensuring safety.

3. Reducing Supply Issues

  • Gradual introduction of new rules to prevent sudden market changes.
  • Transition periods to help manufacturers adjust without affecting patient access.

Updated MHRA Guidance

The MHRA has issued new guidelines to help the industry transition:

  • Conformity Assessment: Clearer guidelines for working with UK-approved bodies.
  • UKCA Marking: Revised timelines and transitional arrangements to support smoother compliance.
  • International Recognition: Easier entry for devices approved in trusted regions.

Impact on the Industry

  • Manufacturers need to enhance monitoring systems and prepare for future technical documentational requirements.
  • Sponsors should align product portfolios with new pathways and prepare for possible reclassifications.

Conclusion

The UK is creating a balanced regulatory framework to ensure safety, foster innovation, and maintain supply stability. By simplifying assessments, updating UKCA marking, and introducing new pathways, the UK aims to stay appealing to med-tech innovators while keeping patients safe.

Manufacturers must align documentation with MHRA guidance, and position the portfolio for recognition pathways to stay ahead of the phased UK MDR reform.

To read more visit www.gov.uk

European Updates

EU Releases Manufacturer’s Trend Report Form (MTR) – Version 1.0

European Commission Proposal COM (2025)1023 – Transforming MedTech Regulation

On December 16, 2025, the European Commission published its proposal COM (2025)1023 final, updating the Medical Device Regulation (MDR, EU 2017/745) and In Vitro Diagnostic Regulation (IVDR, EU 2017/746). This change reform addresses long-lasting concerns about regulatory complexity, excessive administrative burdens, and certification blockages that have seriously impacted small businesses and innovation in the €170 billion European med-tech sector.

Key Highlights

  • SME Relief: Fee reductions (≥50% for micro, ≥25% for small enterprises), flexible PRRC requirements, and dedicated EMA support.
  • Innovation Pathways: Breakthrough Device Pathway, Orphan Device Status, and Regulatory Sandboxes to accelerate access for novel technologies and rare disease treatments.
  • Certification Simplification: Certificates without expiry, limited CECP scope, and removal of PECP for IVDs to reduce bottlenecks.
  • Classification Updates: Down classification of certain software and its accessories, reducing NB involvement allowing oversight on high risk devices.
  • AI & Cybersecurity: Alignment with the AI Act, clear cybersecurity requirements, expanded PMS, and AI sandboxes for safe innovation.
  • Digitalisation: Mandatory Eudamed use, strengthened UDI integration, digital vigilance reporting, and SME support portals.
  • International Cooperation: Stronger collaboration with IMDRF, WHO, and ISO/IEC to harmonise standards and reduce duplication.
  • Combined Studies: Joint MDR/IVDR study applications, harmonised templates, and integrated PMS for efficiency.

Impact

The Commission’s proposal COM (2025) focuses on simplifying regulations and supporting innovation across the med tech ecosystem. The reforms aim to simplify compliance, support SMEs, accelerate innovation, and maintain patient safety. This positions Europe as a global leader in med tech regulation, ensuring safe and innovative devices reach patients faster.

To read the full blog visit Sushvin: https://lnkd.in/gMJBBPrj

EUDAMED User Guide: UDI Devices Update 3.022

The European Commission has released a new update for the EUDAMED User Guide focused on UDI Devices (Release 3.022, December 12, 2025). This update is available for testing in the Playground environment, offering a preview of changes that will soon be implemented in the live Production environment.

What's New in Release 3.022

  • Simplified UDI Registration to minimize errors and enhance data consistency.
  • Improved integration between Basic UDI-DI, certificates, and technical documentation.
  • Bulk upload option for large device portfolios.
  • User-friendly interface to simplify workflows.

Importance

  • Faster identification of counterfeit or non-compliant devices.
  • Stronger post-market surveillance and recall management.
  • Alignment with global UDI systems like FDA GUDID.

Preparing for Compliance

  • Explore bulk upload options.
  • Review links between Basic UDI-DI and certificates.
  • Train teams on new processes.
  • Ensure labeling aligns with UDI standards.

Conclusion

Release 3.022 is not just a technical update but a preparation step for the full EUDAMED rollout. Early engagement will ensure smooth transition and improved patient safety.

To read more visit https://lnkd.in/egDVR_s

EU Health Technology Assessment Regulation – December 2025 Update

The EU Health Technology Assessment Regulation (HTAR) officially entered into force in January 2022. In December 2025, the European Commission released an updated rolling implementation plan.

Key Highlights

Governance – HTA Coordination Group

  • Multiple meetings held on guidance and joint clinical assessments.
  • Published member lists and declarations of interest.

Implementing Acts

  • January 2025: Joint scientific consultation rules adopted.
  • October 2025: Joint clinical assessment rules adopted.

Guidance Documents

  • Finalized guidance for joint clinical assessments.
  • Templates and Q&A documents published.

Stakeholder Engagement

  • HTA Stakeholder Network meetings held.
  • Preparations for HTAR evaluation initiated.

IT Infrastructure

  • Secure information sharing system expanded.
  • Further improvements planned for 2025.

Awareness & Outreach

  • Webinars and conferences conducted.
  • Factsheets and guidance documents released.

Conclusion

The December 2025 update signals the shift from preparation to full implementation. By 2030, HTAR will cover all new medicines and selected devices.

To learn more visit https://lnkd.in/e9Tewt7V

TÜV SÜD’s White Paper for MedTech Start-Ups

MedTech start-ups are known for their creativity and speed entry to the market. However, between creating a prototype and reaching patients, there is a complex regulatory process that can delay market entry and upset investors if not handled well. TÜV SÜD has published a new white paper, “What MedTech Start-Ups Need to Know”, to guide founders in integrating regulatory knowledge early in their process.

Key highlights

Regulator Success Factor

  • Innovation is important, but regulatory confidence is equally vital.
  • Start-ups that focus on compliance early gain trust from investors and regulators.

Seven Topics for a Regulatory Roadmap

The white paper outlines seven critical areas for MedTech start-ups:

  • Intended Use → Precise wording defines the regulatory path.
  • Classification under MDR → Especially important for software and AI devices.
  • Quality Management System (ISO 13485) → Crucial even in early stages of development.
  • Design Control → Structured development ensures readiness for audits.
  • Clinical Evaluation (CER) → Should be planned from the beginning.
  • Post-Market Surveillance (PMS/PMCF) → Continuous learning ensures compliance.
  • Market Access (CE vs FDA) → Strategic differences for international growth.

Importance

  • For founders it provides a roadmap to avoid delays and regulatory issue
  • For industry it aligns with EU MDR and FDA pathways.
  • For patients it ensures devices are safe and effective.

Conclusion

TÜV SÜD’s white paper is more than a compliance guide it’s a strategic plan for MedTech start-ups. By focusing on regulatory, founders can enter the market faster, build investor confidence, and ensure patient safety.

For guidance visit Sushvin: https://lnkd.in/ghhvbEec

Download the white paper: https://lnkd.in/gDVE_Rhz

EMA December 2025 Q&A – Integral Drug–Device Combinations

On December 1, 2025, the European Medicines Agency (EMA) published Revision 6 of its Questions & Answers guidance for applicants, marketing authorisation holders (MAHs), and notified bodies. This update explains how the Medical Device Regulation (EU) 2017/745 (MDR) and In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR) apply when medicinal products and medical devices are combined.

Key Highlights

1.Regulatory Framework

  • If a product combines a drug and a medical device, it will fall under either MDR or the Directive 2001/83/EC, based on its main function.
  • If the main function is medical, it’s regulated as a medical device and needs CE marking.
  • If the main function is medicinal, it’s regulated as a medicinal product, but the device part must meet MDR Annex I safety standards.
  • Lifecycle management obligations.

2.Integral Drug–Device Combinations (iDDCs)

  • Device parts must meet MDR Annex I safety and performance requirements.
  • Article 117 of Regulation (EU) 2017/745 requires that the marketing authorization application for a drug-device combination (DDC) must include the results of the conformity assessment for the device part, if available.
  • If the results are not included and a certificate is needed for the device when used alone, the applicant must get an opinion from a notified body on whether the device meets the safety and performance standards of Annex I to Regulation (EU) 2017/745.
  • For Class I medical devices (excluding Is and Im), if a Declaration of Conformity is not available, a statement from the Marketing Authorization Holder (MAH) confirming compliance with the relevant GSPRs can be accepted.
  • Article 117 applies to certain drug-device combinations mentioned in MDR Articles 1(8) and 1(9).
  • Not apply to combined advanced therapy medicinal products as defined in Article 2(1)(d) of Regulation (EC) No 1394/2007.

3. Co Packaged Devices

Co-packaged products differ from integral drug-device combinations regulated by Directive 2001/83/EC, Regulation (EC) No 726/2004, or Regulation (EU) No 2017/745. The device must comply with the Medical Device Regulation (MDR), including Annex I requirements for safety and performance details.

4. Lifecycle Management

  • The manufacturer must ensure the device meets MDR standards, including any changes to the device.
  • If changes require a new or updated EU certificate, it must be included in a suitable regulatory process after authorisation.
  • If changes require a new or updated notified body opinion or MAH’s GSPRs compliance statement, these must also be included in the appropriate post-authorisation regulatory process.

Importance

Manufacturers must plan early to have device conformity evidence ready during MAA submission to avoid delays.

If in doubt consult Sushvin: https://lnkd.in/gye3ePan

Email: info@sushvin.com

USA Updates

FDA’s 2025 Guidance on Real World Evidence

FDA’s 2025 Guidance on Real World Evidence

On 18 December 2025, the U.S. Food and Drug Administration (FDA) issued its final guidance on the use of Real-World Evidence (RWE) in medical devices regulatory decision-making, marking a significant regulatory milestone. This document replaces the 2017 guidance and reflects advancements in digital health and patient-centered care.

Key Highlights

  • RWE now support submissions across the total product life cycle (510(k), PMA, De Novo, IDE, post market surveillance).
  • FDA will assess RWD based on relevance (availability, timeliness, generalizability) and reliability (quality, integrity).
  • Use of registries as external controls, long-term post-market safety and performance tracking, AI/ML-based medical device monitoring, and biomarker validation.

Real World Evidence

  • RWD: Data collected outside traditional clinical trials, such as electronic health records (EHRs), claims data, and patient-generated data from wearables.
  • RWE: Clinical evidence derived from RWD to understand device usage, benefits, and risks.

FDA emphasizes that RWE can complement or replace traditional clinical studies when appropriately designed and analyzed.

Importance of the Guidance

The 2025 guidance aligns with commitments under the Food and Drug Omnibus Reform Act (FDORA) and MDUFA V. Key benefits of RWE include capturing broader clinical experiences, improving generalizability, allowing long-term tracking, supporting AI-enabled devices, and potentially reducing time to market for innovative devices.

Application

RWE applies across the total product life cycle (TPLC) of medical devices, including premarket submissions, investigational device exemptions, postmarket surveillance, post-approval studies, and AI/ML monitoring. While RWE usage is not mandated, FDA encourages sponsors to consider it when appropriate.

Conclusion

FDA’s 2025 guidance on RWE represents a paradigm shift in medical device regulation, opening doors to more efficient and innovative pathways for device approval. Manufacturers who embrace robust data systems and transparent methodologies will be well-positioned to accelerate innovation while ensuring patient safety.

Australian Updates

Regulatory Update – Australia (Effective 1 Jan 2026)

Regulatory Update – Australia (Effective 1 Jan 2026)

The Therapeutic Goods Administration (TGA) has issued new guidelines on boundary and combination products to help determine whether a product is classified as a medicine, biological, medical device, or other therapeutic good (OTG).

Key Highlights:

  • Boundary Products: Classification depends on the main therapeutic effect, claims, and intended use.
    • Alcohol swabs: Considered a medicine if used for antiseptic purposes, a device if used for cleaning.
    • Nasal sprays: A device if used for physical washing, a medicine if it has a pharmacological action.
    • Toothpastes: A device if used for barrier action, a medicine if containing active ingredients like potassium nitrate.
  • Combination Products:
    • Medicine–device combos (e.g., pre-filled auto-injectors) are regulated as medicines.
    • Devices with added medicinal substances (e.g., heparin-coated catheter) are regulated as medical devices.
    • Biological-device combos (e.g., stents coated with endothelial cells) are regulated as biological products.
  • Transition Period: Existing ARTG entries must align with new pathways by 31 Dec 2030.
  • New Inclusions: From 1 Jan 2026, all new ARTG entries must follow the correct pathway at the time of inclusion.

Implications for Sponsors & Manufacturers:

  • Review current ARTG entries to ensure they are correctly categorized.
  • Clearly define the mode of action and claims to avoid misclassification.
  • Prepare for changes and regulatory submissions during the transition period.

Final Thought: This update provides clarity on boundary and combination products for the industry, ensuring products are regulated under the most appropriate framework. Sponsors should act early to align with the new rules and avoid compliance risks.

To read more visit the official website

Malaysia Updates

Malaysia’s Draft Guidance on Change Management for Medical Devices

Malaysia’s Draft Guidance on Change Management for Medical Devices

The Medical Device Authority (MDA) in Malaysia has released a draft guidance document for public comment from December 2-16, 2025 on Change Management for Registered Medical Devices. This guidance helps manufacturers, importers, and healthcare professionals follow the Medical Device and IVDs under Act 737. It uses a risk-based framework for system to manage changes to registered medical devices, ensuring they remain safe and effective.

    Key Highlights

    Scope

  • Applies to all registered medical devices under Act 737.
  • Includes changes due to post-market issues and updates for re-registration.

Categorisation of Changes

  • Significant Changes: May affect safety or performance (e.g., changes in manufacturing or design).
  • Non-significant Changes: Minor updates with little impact (e.g., label corrections).
  • Flowcharts in Annex B guide the categorisation process.

Reporting Pathways

  • Significant Changes: Need MDA approval before market release.
  • Non-significant Changes: Can often be implemented immediately or require documentation in the Quality Management System (QMS).

UDI-DI

Certain changes need a new Unique Device Identifier (UDI-DI) for tracking.

Bundling of Changes

Multiple changes can be submitted together if they apply to the same certificate

Updates Before Re-Registration

Devices must be updated before re-registration, with specific requirements for different classes.

Software as a Medical Device (SaMD) PCCP

Changes to software must be managed to ensure safety and performance through Predetermined Change Control.

Replacement Reagents & Instruments

Allows adding low/medium-risk reagents to registered instruments, relying on the manufacturer's QMS.

Importance of the Guidance

  • For Manufacturers: Clear processes for managing changes.
  • For Healthcare Providers & Patients: Assurance of safety and -effectiveness.
  • For Industry: Aligns with global best practices.

Conclusion

This draft guidance represents a move towards consistent, risk-based regulation. It ensures that changes in medical devices are safe and well-managed. Stakeholders are encouraged to review and provide feedback to help create a balanced regulatory framework.

Saudi Food and Drug Authority (SFDA) Updates

Understanding SFDA’s New Labelling Templates

Understanding SFDA’s New Labelling Templates

Introduction

The Saudi Food and Drug Authority (SFDA) has updated its templates for Labelling Information, Summary of Product Characteristics (SPC), and Patient Information Leaflets (PIL) to Version 1.3. Companies selling medicinal products in Saudi Arabia must use these templates to meet regulations and get approval.

What's New in Version 1.3

The main change is in Appendix 4: Recommended Labelling Statements.

  • Table 1 updated: Revised statements for finished pharmaceutical products.
  • Table 2 added: Additional labelling requirements needed for stability testing demonstrating limiting factors.

These changes help labels show real-world stability data, enhancing transparency for healthcare providers and patients.

Purpose

The templates are for medicinal products intended for human use. They aim to:

  • Standardize information submitted to SFDA.
  • Follow GCC guidance on labelling, SPC, and PIL.
  • Ensure consistency across all packaging and documents.

Key Labelling Requirements

SFDA requires certain details on both outer and immediate packaging, including:

  • Product name, strength, and pharmaceutical form.
  • Active ingredients and other contents.
  • How to use the product and warnings.
  • Manufacturing and expiry dates.
  • Storage and disposal instructions.
  • Manufacturer details.
  • Batch number and supply classification.
  • DataMatrix barcode, Global Trade Item Number (GTIN), and Serial number (SN).

Even small packages must have basic details to ensure traceability.

Task for Companies

  • Review current packaging and PILs against Version 1.3.
  • Update artwork and text to include mandatory particulars (GTIN, DataMatrix, serial numbers).
  • Ensure bilingual compliance in Arabic and English for PILs.
  • Train regulatory and design teams on formatting rules.
  • Coordinate with stability teams to incorporate new labelling statements where required.

Conclusion

The SFDA’s new templates for labelling, SPC, and PIL align with global best practices in pharmaceutical regulation. By standardizing information and improving patient communication, Saudi Arabia strengthens its regulatory framework.

Companies must align with Version 1.3 now for compliance, to avoid delays, and to build trust with regulators and patients.

To read more visit https://www.sfda.gov.sa/en

IMDRF Updates

IMDRF Draft on Predetermined Change Control Plans (PCCPs) for Medical Device Software

IMDRF Draft on Predetermined Change Control Plans (PCCPs) for Medical Device Software

The International Medical Device Regulators Forum (IMDRF) issued a draft document detailing the Essential Principles and Content of Predetermined Change Control Plans (PCCPs) for medical device software, including Software as a Medical Device (SaMD).

What Are PCCPs?

A Predetermined Change Control Plan (PCCP) is a framework that allows manufacturers to propose and obtain authorization for certain planned changes to medical device software. Instead of submitting a new regulatory application for each change, PCCPs enable pre-authorized, structured updates within the device’s intended use.

A PCCP typically includes:

  • Description of Changes – Detailed planned modifications and rationale.
  • Change Plan – Verification, validation, acceptance criteria, and deployment procedures.
  • Impact Assessment – Evaluation of risks, benefits, and cumulative effects of changes.

Essential Principles of PCCPs

The draft outlines five key principles:

  • Focused and bounded – Changes must stay within the device’s intended purpose.
  • Risk-based – PCCPs must incorporate risk management practices.
  • Evidence-based – Continuous evidence across the Total Product Lifecycle (TPLC) supports safety and effectiveness.
  • Transparent – Clear communication to regulators and users about changes.
  • Lifecycle perspective (TPLC) – Ongoing consideration of user needs, new data, and risk management throughout the device lifecycle.

Benefits of PCCPs

  • For patients this allows for faster access to enhanced medical device software, improving health outcomes and reducing risk of outdated technologies.
  • For Manufacturers this streamlined regulatory processes, reduces burden of multiple submissions and facilitates quicker time-to-market.

Challenges of PCCPs

  • Submission Complexity: Preparing PCCPs requires extensive documentation upfront.
  • Jurisdictional Variability: Adoption of PCCPs may differ across regions, complicating global reliance strategies.
  • Traceability: Strong version control and documentation are essential to prevent confusion.
  • Communication: Clear labelling and user notifications must accompany updates to ensure safe use.

Conclusion

The IMDRF’s draft on Predetermined Change Control Plans (PCCPs) represents a forward-looking method for regulating medical device software. By allowing structured, pre-authorized updates, PCCPs can boost innovation while protecting patients and healthcare systems.

This draft is a call to integrate PCCPs into quality and risk management systems.

For guidance visit Sushvin https://www.sushvin.com/

To read more visit https://lnkd.in/g-FUefst

Council for International Organizations of Medical Sciences (CIOMS)

Understanding the CIOMS Report on AI in Drug Safety

Artificial Intelligence (AI) is changing healthcare, and drug safety monitoring. In 2025, the Council for International Organizations of Medical Sciences (CIOMS) published a report about using AI in pharmacovigilance (PV). This report guides how regulators, industry, and healthcare professionals can responsibly use AI in drug safety systems.

Key Insights from the CIOMS Report

1. Applications of AI in PV

  • Handling Reports: AI can automate the collection and sorting of adverse event reports.
  • Detecting Signals: Machine learning helps identify new safety concerns quicker.
  • Reporting: Streamlines the creation of safety update reports and risk management plans.
  • Screening Literature: AI tools scan large volumes of publications for relevant safety data.
  • Engaging Patients: Chatbots and digital platforms can gather real-world safety information.

2. Challenges & Risks

  • Data Issues: AI is only as good as the data it uses.
  • Transparency: Complex algorithms may not be easily understood by regulators.
  • Accuracy: Too much reliance on automation might miss important signals or create false alarms.
  • Workforce Changes: Balancing automation with human expertise in PV is important.

3. Governance & Ethical Considerations

  • CIOMS treat AI tools with the same care as medicinal products, with clear indications, contraindications, and precautions.
  • Encourage global consistency in AI methods used in PV.
  • Support joint regulatory strategies to ensure uniformity across regions.

Importance

  • For industry it offers guidance on responsibly using AI in safety monitoring.
  • For patients it ensures AI leads to safer, quicker detection of drug risks.

Conclusion

The CIOMS report sees AI as a powerful tool in drug safety, but it must be well-regulated. While AI can improve efficiency, human oversight, ethical standards, and global cooperation are crucial.

AI in PV is a valuable addition to human expertise, not a replacement. The CIOMS framework ensures AI enhances drug safety without compromising trust.

To read more visit https://lnkd.in/dK3E9_hD

ISO Updates

ISO Medical Device Standards Update – November 2025

Medical Device Standards Update

The International Organization for Standardization (ISO) has issued its December 2025 update.

Key Medical Device Standards in Development

New sterilization standards:

  • ISO/CD TS 20327 – Guidelines for handling and storing sterile medical devices.
  • ISO/FDIS 10993-7 – Updated standards for ethylene oxide sterilization.
  • ISO/DIS 7864 – Revised standards for sterile hypodermic needles.
  • ISO/DIS 7886-1 – Updated guidelines for sterile hypodermic syringes.

Implants & Surgical Instruments

Enhanced standards:

  • ISO/FDIS 6335-1 & 6335-2 – Requirements for surgical staplers.
  • ISO/CD 24466 – Standards for implant parts in dentistry.
  • ISO/CD TS 17137 – Standards for cardiovascular absorbable implants.
  • ISO 7206-12:2025 – New deformation test for hip joint prostheses.

Digital Health & Cybersecurity

  • ISO/DTS 6268-3 – Cybersecurity framework for telehealth.
  • ISO/DTS 5137 – Management of medical device maintenance.

New biobanking standards:

  • ISO/CD 22859 – Requirements for cells from umbilical cord tissue.
  • ISO/CD 24651 – Standards for bone marrow-derived cells.
  • ISO/FDIS 20012 – Standards for cells from pluripotent stem cells.
  • ISO/CD 25448 – Vocabulary for organ-on-chip systems.

Updated diagnostic standards:

  • ISO/FDIS 18704 – Requirements for cell-free DNA processes.
  • ISO/CD TS 8219 – Sequencing standards for infectious diseases.

Quality Management & Regulatory Alignment

Biological Evaluation Updates

Revised evaluation standards:

  • ISO/FDIS 10993-7 – Major revision for ethylene oxide sterilization.
  • ISO 10993-17:2023/Amd 1:2025 – New amendment for toxicological risk assessment.

ISO/DIS 24031 – General requirements for bio-devices.

Updated information systems:

  • ISO/DIS 11616 – Identification of pharmaceutical products.
  • ISO/AWI 21526.2 – Metadata repository requirements.

Recent important standards:

  • ISO 17510:2025 – Sleep apnea therapy masks.
  • ISO 6876:2025 – Endodontic sealing materials.
  • ISO 11040-3:2025 – Seals for dental anesthetic cartridges.
  • ISO 18192-3:2025 – Testing for spinal disc prostheses.
  • ISO 6631:2025 – Collagen marker quantification.

Withdrawn & Replaced Standards

ISO/TS 16843-1:2016 replaced by ISO 16843-1:2025.

Immediate Implications:

  • Sterilization Processes: Changes in ethylene oxide standards will affect validation protocols.
  • Material Specifications: New stainless-steel requirements impact supply and testing.
  • Digital Security: New telehealth cybersecurity standards highlight regulatory focus.

Areas to Watch in 2026

  • AI in Medical Devices: Adjacent AI standards will affect diagnostic software.
  • Sustainability Requirements: Environmental factors may appear in device manufacturing.

For more details visit the ISO website.

For guidance visit Sushvin https://lnkd.in/gye3ePan

Sushvin Provides UK Responsible Person (UK RP) Services

Are you a legal medical device/IVD manufacturer located outside the UK and would like to market your product in the UK, then you will require a UK responsible person who will act on behalf of the manufacturer to ensure all the responsibilities detailed within the updated UK MDR 2002 regulations are met.

As a legal manufacturer, organisations will have to register their devices prior to be placed on the UK market.

If you need UK Responsible Person (UK RP) services, please contact SUSHVIN for more information.

If you are planning to market your product in the EU and if you require PRRC (Person Responsible for Regulatory Compliance), we have a team of experienced regulatory professionals who can help you assist with PRRC services and get you regulatory compliant as per MDR 2017/745 and IVDR 2017/746
If you need PRRC Services, please contact SUSHVIN for more information.

Discover Our Range of Services

Sushvin provides a wide range of services designed to cater to the diverse needs of our clients. Our extensive service offerings include:

Subscribe To Our Newsletter

For Latest Updates, Subscribe to our monthly newsletter today!